A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Arun J SanyalPierre BedossaMandy FraessdorfGuy W NeffEric LawitzElisabetta BugianesiQuentin M AnsteeSamina Ajaz HussainPhilip Noel NewsomeVlad RatziuAzadeh Hosseini-TabatabaeiJörn Markus SchattenbergMazen NoureddinRohit L LoombaRamy Younesnull nullPublished in: The New England journal of medicine (2024)
Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).